Integrin β3 links therapy resistance and cancer stem cell properties.
Heterogeneity in tumour cell properties underlies many treatment failures. Understanding the sources of such heterogeneity has proved to be challenging, but remains critical to improving patient outcomes. Integrin α(v)β₃ expression in multiple types of solid tumour stem cells is now shown to control a pro-survival pathway that contributes to therapy resistance.